atrial fibrillation
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or older; 2. Diagnosed with paroxysmal or persistent atrial fibrillation and undergoing surgery; 3. Voluntarily willing to participate in this study and sign the informed consent form. If the participant is unable to read or sign the informed consent form due to lack of capacity, their guardian should act on their behalf to go through the informed process and sign the consent form. If the participant is unable to read the informed consent form (e.g., illiterate participants), a witness must witness the informed process and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to anticoagulation; 2. Known severe comorbidities with an expected survival of less than 1 year; 3. Myocardial infarction (MI) within the past 3 months, or having undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI); 4. Left atrial anteroposterior diameter >55 mm; 5. LVEF <30%; 6. NYHA functional class III or IV; 7. Planned heart transplantation or other cardiac surgery within 12 months; 8. Record of thromboembolic events in the past 6 weeks; 9. Currently participating in a study evaluating other devices or drugs; 10. Acute illness, active systemic infection, or sepsis; end-stage renal disease (eGFR <15 mL/min/1.73m²) or on dialysis; terminal malignancy; 11. Other congenital anomalies or medical issues judged by the investigator to significantly prevent patient participation in this study; 12. Vulnerable populations other than illiterate or elderly individuals, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| medical data; | — |
Countries
China
Contacts
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University